Challenging scenario for sure. Clinical trial could be preferred here - studies in this space include bispecific antibodies, CDK9 inhibitors, and TCA inhibitors, among others. Standard-of-care wise, presuming that biopsy confirms retention of CD19 expression, there is a literature establishing activ...